• MHS Preferred Drug List (PDL) Updates – Q1 2016

    View the following information as a PDF MHS routinely reviews the medications available on the Preferred Drug List (PDL). Items are added, removed or modified periodically due to industry standards, market availability, and assessment of use. Below is a list of changes that were approved by the MHS P&T Committee this quarter. MHS will transition…

    Read More...
  • Attention Members and Providers: Tudorza Pressair Inhaler Recall

    Attention Members and Providers: MHS wants you to know about a recent drug recall. The U.S. Food and Drug Administration (FDA) issued an Enforcement Report regarding AstraZeneca Pharmaceuticals LP. It is for Tudorza Pressair Inhaler (aclindinium bromide inhalation powder), 400 mcg per actuation, 60 Metered Doses per inhaler (prescription only). The FDA issued the recall…

    Read More...
  • Member Eligibility Notification

    Member Eligibility Notification  MHS recently sent some members a letter by mistake, stating that the member’s HIP coverage was ending on April 30th. We have notified the affected members and assured them that their coverage remains current, with no break in coverage. MHS apologizes if this error caused any confusion. Please remember to always check…

    Read More...
More News